Pfizer says its JAK drug topped Dupixent in a head-to-head eczema test — but you'll have to wait on the data
Just a few hours after Sanofi and Regeneron unveiled a new slate of data for Dupixent in children with eczema, Pfizer released its own results for a JAK challenger. And they come from the first such trial showing a direct head-to-head comparison between the two.
The New York-based drug giant uncorked topline data from a Phase III study pitting its abrocitinib against Dupixent, saying the experimental drug notched superiority over the blockbuster in moderate to severe atopic dermatitis. Abrocitinib met both primary endpoints, Pfizer said, with a higher proportion of patients achieving at least a four-point improvement over baseline in an itchiness scale and at least 90% improvement on an eczema index.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.